drugset / Trial / NCT06567457
Immunogenicity and Safety Study of Monovalent Omicron XBB.1.5 Vaccine as a Booster in Adults
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to assess the immunogenicity and safety of SCB-2023B monovalent Omicron XBB.1.5 vaccine compared to the prototype SCB-2019 vaccine in participants previously vaccinated with 3 doses of inactivated COVID-19 vaccine ≥6 months prior to enrollment.
Timeline
- Start
- 2023-10
- Primary completion
- 2024-09
- Completion
- 2024-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | SCB-2019 | Vaccine | — | Intramuscular |
| Subject | SCB-2023B | Vaccine | — | Intramuscular |